Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice
Niels S. Vermeer, Thijs J. Giezen, Sofia Zastavnik, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 105, Iss. 4, pp. 962-969
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
KM Morrissey, TM Yuraszeck, Chi‐Chung Li, et al.
Clinical and Translational Science (2016) Vol. 9, Iss. 2, pp. 89-104
Open Access | Times Cited: 164
Evolution of the EU Biosimilar Framework: Past and Future
Elena Wolff‐Holz, Klara Tiitso, Camille Vleminckx, et al.
BioDrugs (2019) Vol. 33, Iss. 6, pp. 621-634
Open Access | Times Cited: 104
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
Hillel P. Cohen, Matthew Turner, Dorothy McCabe, et al.
BioDrugs (2023) Vol. 37, Iss. 5, pp. 583-593
Open Access | Times Cited: 18
Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial
Marie-Christine Bielsky, Anne Cook, Andrea Wallington, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 11, pp. 1910-1918
Open Access | Times Cited: 43
The Importance of Countering Biosimilar Disparagement and Misinformation
Hillel P. Cohen, Dorothy McCabe
BioDrugs (2020) Vol. 34, Iss. 4, pp. 407-414
Open Access | Times Cited: 42
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Eduardo Mysler, Valdeŕilio Feijó Azevedo, Silvio Danese, et al.
Drugs (2021) Vol. 81, Iss. 16, pp. 1859-1879
Open Access | Times Cited: 37
Are we ready to close the discussion on the interchangeability of biosimilars?
Hans C. Ebbers, Huub Schellekens
Drug Discovery Today (2019) Vol. 24, Iss. 10, pp. 1963-1967
Open Access | Times Cited: 41
Current state of biologic pharmacovigilance in the European Union: improvements are needed
Thomas Felix, John B. Jordan, Catherine Akers, et al.
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 3, pp. 231-240
Open Access | Times Cited: 31
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies
Elena Guillén, Niklas Ekman, Sean Barry, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 1, pp. 108-123
Open Access | Times Cited: 17
The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries
Kevin Klein, Mümün Gencoglu, Jens Heisterberg, et al.
BioDrugs (2022) Vol. 37, Iss. 2, pp. 235-245
Open Access | Times Cited: 10
Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review
Ali M. Alsamil, Thijs J. Giezen, Toine C. G. Egberts, et al.
European Journal of Pharmaceutical Sciences (2020) Vol. 154, pp. 105501-105501
Open Access | Times Cited: 16
Extrapolation: Experience gained from original biologics
Luisa Fernanda Rojas, Fernando de Mora
Drug Discovery Today (2021) Vol. 26, Iss. 8, pp. 2003-2013
Open Access | Times Cited: 12
Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study
Hanna M. Tolonen, Marja Airaksinen, Päivi Ruokoniemi, et al.
BMJ Open (2019) Vol. 9, Iss. 10, pp. e032892-e032892
Open Access | Times Cited: 12
Cardiotoxicity in Biological Agent-Targeted Therapy for Rheumatoid Arthritis: ADR Signal Mining and Analysis of Food and Drug Administration Adverse Event Reporting System Database
Xiaoyan Tang, Xiaolin Xu, Ji Li, et al.
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 10
Compatibility of immunogenicity guidance by the EMA and the US FDA
Pekka Kurki
Bioanalysis (2019) Vol. 11, Iss. 17, pp. 1619-1629
Closed Access | Times Cited: 10
The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK
Kevin Klein, Lorna Hazell, Pieter Stolk, et al.
Drug Safety (2019) Vol. 43, Iss. 3, pp. 255-263
Open Access | Times Cited: 9
The whole experience of public hospital physicians from several specialties with biopharmaceutical effectiveness, safety, adverse drug reactions and interchangeability: A qualitative study
Hiba Leith Fahmi, Ali Azeez Al‐Jumaili, Manal M. Younus
Exploratory Research in Clinical and Social Pharmacy (2022) Vol. 7, pp. 100162-100162
Open Access | Times Cited: 6
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations
Wallace Brownlee, Christian Wolf, Hans‐Peter Hartung, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 14, pp. 2177-2189
Closed Access | Times Cited: 6
Biosimilar medicines: Why the science matters
Rosa González-Quevedo, Elena Wolff‐Holz, Melanie Carr, et al.
Health Policy and Technology (2020) Vol. 9, Iss. 2, pp. 129-133
Closed Access | Times Cited: 6
Adverse drug reactions associated with the use of biological agents
Jorge Enrique Machado‐Alba, Anyi Liliana Jiménez-Morales, Yulieth Carolina Moran-Yela, et al.
PLoS ONE (2020) Vol. 15, Iss. 12, pp. e0240276-e0240276
Open Access | Times Cited: 6
Patterns of adverse drug reactions in Jordan: a retrospective analysis of the National Pharmacovigilance Data Registry (2015–2021)
Nizar M. Mhaidat, Osama Y. Alshogran, Shoroq M. Altawalbeh, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 10, pp. 957-965
Closed Access | Times Cited: 2
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review
Hanna M. Tolonen, Jenni Falck, Pekka Kurki, et al.
BioDrugs (2021) Vol. 35, Iss. 5, pp. 547-561
Open Access | Times Cited: 5
Pharmacovigilance System in EU
Deepali Siwan, Mukesh Nandave, Anoop Kumar
(2024), pp. 163-182
Closed Access
ASSESSMENT OF COMMUNITY PHARMACIST AWARENESS ON ADVERSE DRUG REACTION (ADR) AND PHARMACOVIGILANCE REPORTING SYSTEM IN KHARTOUM LOCALITY, SUDAN
Ali Awadallah Saeed, Osman Demir, Nauman Ahmed, et al.
Universal Journal of Pharmaceutical Research (2021)
Open Access | Times Cited: 3
Safety Profile of Biological Drugs in Clinical Practice: A Retrospective Pharmacovigilance Study
Elaaf Fadhil Hassan, Dheyaa j Kadhim, Manal M. Younus
Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) (2022) Vol. 31, Iss. 1, pp. 32-42
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top